Aquestive therapeutics reports positive initial topline data from part 3 of epiphast trial evaluating aqst-109 epinephrine oral film

Warren, n.j., june 15, 2022 (globe newswire) -- aquestive therapeutics, inc. (nasdaq: aqst), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today announced positive topline results from the first three arms of part 3 of the epiphast study for its aqst-109 epinephrine oral film.
AQST Ratings Summary
AQST Quant Ranking